Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia
Authors:
- A.D. MaraisAMA.D. Marais
- J. MountneyJMJ. Mountney
- J.C. FirthJFJ.C. Firth
- N.B. RendellNRN.B. Rendell
- G.W. TaylorGTG.W. Taylor
- G.R. ThompsonGTG.R. Thompson
- 1 January 1996
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 119 (2) , 203-213
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- How effective is drug therapy in heterozygous familial hypercholesterolemia?The American Journal of Cardiology, 1993
- The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphismMetabolism, 1993
- Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemiaAtherosclerosis, 1993
- Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemiaAtherosclerosis, 1992
- Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemiaAtherosclerosis, 1990
- The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemiaMetabolism, 1990
- Regulation of the mevalonate pathwayNature, 1990
- Multiple crm- mutations in familial hypercholesterolemia. Evidence for 13 alleles, including four deletions.Journal of Clinical Investigation, 1988
- Lovastatin (Mevinolin) in the Treatment of Heterozygous Familial HypercholesterolemiaAnnals of Internal Medicine, 1987
- Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.Journal of Clinical Investigation, 1984